文献速递冠心病血脂与心血管预防

秋水仙碱在慢性冠心病患者中的疗效与既往急性冠脉综合征病史及时机的关系

Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome.
PubMed 文献 · J Am Coll Cardiol · 2021-01-01

LoDoCo2 试验随机将慢性冠心病患者分配至秋水仙碱 0.5 mg 每日一次或安慰剂,比较不同既往 ACS 状态(无、近期、远期、极远期)下的主要终点事件率,并评估交互作用。结果显示,无论既往 ACS 病史及时机如何,秋水仙碱的获益一致(交互作用 P=0.59)。

要点

  • 秋水仙碱 0.5 mg 每日一次在慢性冠心病患者中降低主要终点事件风险。
  • 获益不受既往 ACS 病史及距发病时间影响(交互作用 P=0.59)。
  • 近期 ACS 亚组 HR 0.75(95%CI 0.51-1.10),未达统计学显著。

核心结论

  • 秋水仙碱的获益与既往 ACS 病史及时机无关。

研究设计与样本

  • LoDoCo2 试验为随机对照研究,共纳入 5,522 例慢性冠心病患者,随机分配至秋水仙碱 0.5 mg 每日一次或安慰剂。

主要发现

  • 无既往 ACS 患者:秋水仙碱组 vs 安慰剂组主要终点发生率 2.8 vs 3.4 事件/100 人年,HR 0.81,95%CI 0.52-1.27。
  • 近期 ACS(6-24 个月)患者:2.4 vs 3.3 事件/100 人年,HR 0.75,95%CI 0.51-1.10。
  • 远期 ACS(2-7 年)患者:1.8 vs 3.2 事件/100 人年,HR 0.55,95%CI 0.37-0.82。
  • 极远期 ACS(>7 年)患者:3.0 vs 4.3 事件/100 人年,HR 0.70,95%CI 0.51-0.96。
  • ACS 状态与秋水仙碱疗效的交互作用 P=0.59。

临床怎么用

  • 慢性冠心病患者使用秋水仙碱 0.5 mg 每日一次进行二级预防时,无需考虑既往 ACS 病史及时机。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Colchicine reduces risk of cardiovascular events in patients post-myocardial infarction and in patients with chronic coronary disease. It remains unclear whether this effect is related to the time of onset of treatment following an acute coronary syndrome (ACS). OBJECTIVES: This study investigates risk for major adverse cardiovascular events in relation to history and timing of prior ACS, to determine whether the benefits of colchicine are consistent independent of prior ACS status. METHODS: The LoDoCo2 (Low-Dose Colchicine 2) trial randomly allocated patients with chronic coronary disease to colchicine 0.5 mg once daily or placebo. The rate of the composite of cardiovascular death, spontaneous myocardial infarction, ischemic stroke, or ischemia-driven coronary revascularization was compared between patients with no prior, recent (6-24 months), remote (2-7 years), or very remote (>7 years) ACS; interaction between ACS status and colchicine treatment effect was assessed. RESULTS: In 5,522 randomized patients, risk of the primary endpoint was independent of prior ACS status. Colchicine consistently reduced the primary endpoint in patients with no prior ACS (incidence: 2.8 vs 3.4 events per 100 person-years; hazard ratio [HR]: 0.81; 95% confidence interval [CI]: 0.52-1.27), recent ACS (incidence: 2.4 vs 3.3 events per 100 person-years; HR: 0.75; 95% CI: 0.51-1.10), remote ACS (incidence: 1.8 vs 3.2 events per 100 person-years, HR: 0.55; 95% CI: 0.37-0.82), and very remote ACS (incidence: 3.0 vs 4.3 events per 100 person-years, HR: 0.70; 95% CI: 0.51-0.96) (P for interaction = 0.59). CONCLUSIONS: The benefits of colchicine are consistent irrespective of history and timing of prior ACS. (The LoDoCo2 Trial: Low Dose Colchicine for secondary prevention of cardiovascular disease [LoDoCo2] ACTRN12614000093684).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Opstal TSJ, Fiolet ATL, van Broekhoven A, et al. Colchicine in Patients With Chronic Coronary Disease in Relation to Prior Acute Coronary Syndrome. J Am Coll Cardiol. 2021. PMID: 34446156. doi:10.1016/j.jacc.2021.06.037

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。